Capricor Therapeutics, Inc. (CAPR)

NASDAQ: CAPR · IEX Real-Time Price · USD
4.51
0.00 (0.00%)
At close: Jun 24, 2022 4:00 PM
4.71
+0.20 (4.43%)
After-hours: Jun 24, 2022 6:04 PM EDT
0.00%
Market Cap 109.70M
Revenue (ttm) 204,082
Net Income (ttm) -22.69M
Shares Out 24.32M
EPS (ttm) -0.96
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 175,851
Open 4.58
Previous Close 4.51
Day's Range 4.50 - 4.60
52-Week Range 2.56 - 5.85
Beta 5.39
Analysts Buy
Price Target 15.30 (+239.2%)
Earnings Date Aug 11, 2022

About CAPR

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company al... [Read more...]

Industry Biotechnology
Founded 2005
CEO Linda Marban
Employees 48
Stock Exchange NASDAQ
Ticker Symbol CAPR
Full Company Profile

Financial Performance

In 2021, CAPR's revenue was $244,898, a decrease of -21.06% compared to the previous year's $310,250. Losses were -$20.02 million, 46.6% more than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for CAPR stock is "Buy." The 12-month stock price forecast is 15.3, which is an increase of 239.25% from the latest price.

Price Target
$15.3
(239.25% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Capricor Therapeutics to Present One-Year Efficacy Results from its Ongoing HOPE-2 Open Label Extension Study at 2022...

Results to be Presented in Late-Breaking Session Results to be Presented in Late-Breaking Session

Capricor Therapeutics Appoints Xavier Avat as Chief Business Officer

Capricor Expands Senior Management Team to Build Commercial Strategy for Lead Asset, CAP-1002, and Further Develop Partnering Strategy for Proprietary Exosome Platform

Capricor Therapeutics to Present at the H.C. Wainwright Global Investment Conference

SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatme...

Capricor Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update

-Executed Partnership with Nippon Shinyaku for the Commercialization and Distribution of  CAP-1002 for Duchenne Muscular Dystrophy in the United States-

Capricor Therapeutics to Present First Quarter 2022 Financial Results and Recent Corporate Update on May 10

Company to Host Conference Call, May 10, 2022, at 4:30 p.m. ET Company to Host Conference Call, May 10, 2022, at 4:30 p.m. ET

7 Undervalued Penny Stocks With Major Upside

Each of these penny stocks has proven momentum throughout 2022 and major upside on top of the returns through the the first quarter. The post 7 Undervalued Penny Stocks With Major Upside appeared first ...

Other symbols: CHRAFGILPCNPFIESHIPVGZ

Capricor Therapeutics to Participate in the Cantor Fitzgerald Rare Orphan Disease Summit

SAN DIEGO, March 29, 2022 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatm...

Capricor Shares Fall After Topline Results From Mid-Stage COVID-19 Trial

Capricor Therapeutics Inc (NASDAQ: CAPR) announced topline data from its Phase 2 INSPIRE study evaluating a single-dose intravenous infusion of CAP-1002 for hospitalized COVID-19 patients. Capricor said...

Capricor Therapeutics Reports Topline Results from Phase 2 Exploratory INSPIRE Trial in Severe Hospitalized COVID-19 ...

-Primary Objective of Study Met: CAP-1002 was Safe and Well Tolerated-

The Lancet Publishes Positive Results from Capricor Therapeutics' Phase 2 Study Evaluating CAP-1002 in Late-Stage Duc...

-One-Year Final Data Highlights Lead Cell Therapy Asset, CAP-1002, for Safety and Efficacy in Slowing Upper Limb and Cardiac Function Deterioration in Patients-

Capricor Therapeutics to Present Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Update on M...

Company to Host Conference Call, March 10, 2022, at 4:30 p.m. ET Company to Host Conference Call, March 10, 2022, at 4:30 p.m. ET

Capricor Therapeutics Names Dr. Daniel Paulson as Vice President of Clinical Development

Dr. Paulson Will Lead Clinical Efforts Focused on Capricor's Late-Stage Cell Therapy Program and its Expanding Exosome Platform-- Dr. Paulson Will Lead Clinical Efforts Focused on Capricor's Late-Stage ...

Nippon Shinyaku and Capricor Therapeutics Enter into an Exclusive Partnership for Commercialization and Distribution ...

KYOTO, Japan, Jan. 25, 2022 /PRNewswire/ -- *NS Pharma Note: CAP-1002 is an investigational therapy and not approved in the US. This press release is being provided for a US audience as a reference.

Capricor Therapeutics, Nippon Shinyaku Ink US Pact For Duchenne Muscular Dystrophy Candidate

Capricor Therapeutics Inc (NASDAQ: CAPR) has partnered with Nippon Shinyaku Co Ltd for the exclusive commercialization and distribution in the U.S of Capricor's CAP-1002 for Duchenne muscular dystrophy ...

Capricor Therapeutics and Nippon Shinyaku Enter Partnership for Exclusive Commercialization and Distribution of CAP-1...

-Partnership Leverages Nippon Shinyaku's Deep Experience in Drug Development for Rare Diseases and its Commercial DMD Franchise in the U.S.-

Forget Bargains, Play 5 Stocks With Rising P/E Instead

Forget undervalued stocks, there is room for upside even in stocks with rising P/E.

Other symbols: NDRASAMSIRISTKL

Capricor Therapeutics Announces Key Updates on its Vaccine and Therapeutic Programs for COVID-19

Capricor's Exosome-based mRNA Vaccine for SARS-CoV-2 -In-Vivo Preclinical Data Published in the Journal of Biological Chemistry - -Preclinical Data Demonstrates Strong T-Cell Response for High Conserved...

Here's Why Capricor (CAPR) is Poised for a Turnaround After Losing 19.3% in 4 Weeks

Capricor (CAPR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ea...

Capricor's CEO Dr. Linda Marbán to Serve as Keynote Speaker at TriLink Annual mRNA Day

– The Global, Virtual Event in Partnership with Genetic Engineering News (GEN) and the CRISPR Journal, Taking Place on November 16, 2021 – – The Global, Virtual Event in Partnership with Genetic Enginee...

Capricor Therapeutics (CAPR) Reports Q3 Loss, Lags Revenue Estimates

Capricor (CAPR) delivered earnings and revenue surprises of 22.73% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Capricor Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

CAP-1002 – Capricor's Cell Therapy Program for Duchenne Muscular Dystrophy -Phase 3 Pivotal Study Cleared to Proceed- -Presented Positive Phase 2 HOPE-2 Data at Late-Breaking Oral Presentation at the  W...

Capricor Therapeutics to Present Third Quarter 2021 Financial Results and Recent Corporate Update on November 9

Company to Host Conference Call, November 9, 2021, at 4:30 p.m. ET Company to Host Conference Call, November 9, 2021, at 4:30 p.m. ET

Capricor Stock Is Moving Higher As Duchenne Dystrophy Cell Therapy Slows Disease Progression By 71%

Capricor Therapeutics Inc (NASDAQ: CAPR) has announced final data from Phase 2 HOPE-2 trial of CAP-1002 for advanced stages of Duchenne muscular dystrophy (DMD).  The trial met its primary efficacy endp...

Capricor Therapeutics Announces Positive Final Data From its Phase 2 HOPE-2 Trial in Patients with Duchenne Muscular ...

–Trial Met its Primary Efficacy Endpoint of Mid-level Performance of Upper Limb (PUL) v1.2 (p=0.01)–